BiomX (NYSEAMERICAN:PHGE) Trading Down 8.2%

BiomX Inc. (NYSEAMERICAN:PHGE) dropped 8.2% during mid-day trading on Thursday . The company traded as low as $0.41 and last traded at $0.41. Approximately 145,054 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 1,998,794 shares. The stock had previously closed at $0.44.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of BiomX in a report on Wednesday, April 3rd.

BiomX Trading Down 5.9 %

The stock has a market cap of $21.20 million, a price-to-earnings ratio of -0.72 and a beta of 1.31. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 1.75.

BiomX (NYSEAMERICAN:PHGE) last announced its quarterly earnings data on Wednesday, April 3rd. The company reported ($0.08) EPS for the quarter. Equities research analysts forecast that BiomX Inc. will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. 8VC GP I LLC bought a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 1,086,191 shares of the company’s stock, valued at approximately $304,000. BiomX accounts for 0.3% of 8VC GP I LLC’s investment portfolio, making the stock its 3rd largest holding. 8VC GP I LLC owned about 2.36% of BiomX at the end of the most recent reporting period. 40.57% of the stock is currently owned by institutional investors.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).